Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2022
- Start of clinical trial with HDP-101 in multiple myeloma
- Financing commitment of up to EUR 36 million obtained from main shareholder dievini
- Signing of a strategic partnership with Huadong Medicine with an overall volume of up to one billion US dollars
- Financials in line with planning still without taking into account the partnership with Huadong
Heidelberg Pharma AG today reported on the first three months of fiscal year 2022 (1 December 2021 – 28 February 2022) and the Group’s financial figures.